GTA-002 Market Summary

Key Factors Driving GTA-002 Growth

1. Significant unmet medical need in acute myeloid leukemia

AML is an aggressive blood cancer associated with substantial relapse risk, particularly among patients who remain positive for measurable residual disease (MRD) after achieving morphological remission. Glycostem's Phase I/IIa WiNK study evaluates GTA-002 in AML patients in complete morphological remission with residual disease who do not have a strong indication for stem-cell transplantation. The trial was designed to enroll 33 patients, reflecting a targeted effort to address a population with limited treatment options. This unmet need could support adoption if the therapy demonstrates durable disease control.

2. Early clinical findings supporting further development

In preliminary results reported at the 2022 European Hematology Association (EHA) Congress, Glycostem stated that patients in the first dose cohort achieved some level of MRD negativity. Earlier reporting from the initial two treated patients also described changes in molecular MRD measurements following treatment. These observations provided an early clinical rationale for continued evaluation, but the small number of patients and limited follow-up mean they should not be interpreted as proof of efficacy or improved survival. Larger clinical datasets are needed to determine response durability and clinical benefit.

3. Off-the-shelf availability and manufacturing scalability

Unlike personalized autologous cell therapies, GTA-002 is manufactured in advance from donor-derived cells and cryopreserved for later use. Glycostem's closed, semi-automated manufacturing platform expands and differentiates CD34-positive progenitor cells into NK cells without feeder cells. This approach could support standardized production, inventory management, and faster access to treatment when compared with therapies that require patient-specific manufacturing. If validated at commercial scale, these features may improve operational efficiency and broaden treatment availability.

4. Potential safety advantages of natural killer cells

NK cells can recognize and kill malignant cells through multiple activating receptors and innate immune mechanisms. Unlike conventional donor-derived T-cell therapies, NK-cell therapies may have a lower propensity for graft-versus-host disease, although the actual safety profile depends on the product and treatment regimen. Glycostem's preclinical research describes GTA-002's activity against tumor cell lines and its ability to mediate antibody-dependent cellular cytotoxicity. These characteristics could support its use alone or in combination with antibodies, but clinical safety and efficacy must be established in patients.

5. Potential expansion into solid tumors and autoimmune diseases

Glycostem's published pipeline lists additional development opportunities for GTA-002, including unresectable liver metastases from colorectal cancer and systemic lupus erythematosus (SLE). The company has also reported preclinical activity against melanoma and other tumor models. Expansion beyond AML could diversify its potential future applications and reduce dependence on one indication. However, these programs are at preclinical stages, so their commercial relevance remains uncertain until clinical trials establish meaningful benefit.

GTA-002 Recent Developments

GTA-002 is actively advancing through a Phase I/IIa clinical trial (NCT04632316) treating patients diagnosed with Acute Myeloid Leukemia (AML).

“GTA-002 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of GTA-002 for potential indication like Acute myeloid leukaemia, Multiple myeloma, Colorectal cancer, Malignant melanoma, and Systemic lupus erythematosus in the 7MM. A detailed picture of GTA-002’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the GTA-002 for potential indications. The GTA-002 market report provides insights about GTA-002’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current GTA-002 performance, future market assessments inclusive of the GTA-002 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of GTA-002 sales forecasts, along with factors driving its market.

GTA-002 Drug Summary

GTA-002, also known as inaleucel and marketed under the investigational product name oNKord, is an off-the-shelf, allogeneic natural killer (NK) cell therapy developed by Glycostem Therapeutics for the treatment of hematological malignancies, particularly acute myeloid leukemia (AML). The therapy is manufactured from CD34-positive hematopoietic stem and progenitor cells obtained from umbilical cord blood, which are expanded and differentiated ex vivo into large numbers of activated NK cells using Glycostem’s proprietary manufacturing platform. NK cells are components of the innate immune system that can recognize and destroy malignant cells without requiring the same antigen-specific recognition mechanism as conventional T-cell therapies. GTA-002 is designed as a cryopreserved, ready-to-use cellular product, potentially enabling standardized manufacturing and treatment without collecting and modifying cells from each individual patient. It is administered through intravenous infusion following lymphodepleting conditioning with cyclophosphamide and fludarabine, according to the clinical protocol. Its clinical development has focused on patients with AML who have achieved morphological complete remission but retain measurable residual disease (MRD) and are not proceeding to allogeneic hematopoietic stem cell transplantation. The report provides GTA-002’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the GTA-002 Market Report

The report provides insights into:

• A comprehensive product overview including the GTA-002 MoA, description, dosage and administration, research and development activities in potential indication like Acute myeloid leukaemia, Multiple myeloma, Colorectal cancer, Malignant melanoma, and Systemic lupus erythematosus.
• Elaborated details on GTA-002 regulatory milestones and other development activities have been provided in GTA-002 market report.
• The report also highlights GTA-002‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The GTA-002 market report also covers the patents information, generic entry and impact on cost cut.
• The GTA-002 market report contains current and forecasted GTA-002 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The GTA-002 market report also features the SWOT analysis with analyst views for GTA-002 in potential indications.

Methodology

The GTA-002 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GTA-002 Analytical Perspective by DelveInsight

• In-depth GTA-002 Market Assessment

This GTA-002 sales market forecast report provides a detailed market assessment of GTA-002 for potential indication like Acute myeloid leukaemia, Multiple myeloma, Colorectal cancer, Malignant melanoma, and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted GTA-002 sales data uptil 2034.

• GTA-002 Clinical Assessment

The GTA-002 market report provides the clinical trials information of GTA-002 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

GTA-002 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

GTA-002 Market Potential & Revenue Forecast

• Projected market size for the GTA-002 and its key indications
• Estimated GTA-002 sales potential (GTA-002 peak sales forecasts)
• GTA-002 Pricing strategies and reimbursement landscape

GTA-002 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• GTA-002 Market positioning compared to existing treatments
• GTA-002 Strengths & weaknesses relative to competitors

GTA-002 Regulatory & Commercial Milestones

• GTA-002 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

GTA-002 Clinical Differentiation

• GTA-002 Efficacy & safety advantages over existing drugs
• GTA-002 Unique selling points

GTA-002 Market Report Highlights

• In the coming years, the GTA-002 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The GTA-002 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence GTA-002’s dominance.
• Other emerging products for Acute myeloid leukaemia, Multiple myeloma, Colorectal cancer, Malignant melanoma, and Systemic lupus erythematosus are expected to give tough market competition to GTA-002 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GTA-002 in potential indications.
• Analyse GTA-002 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted GTA-002 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of GTA-002 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of GTA-002? How strong is GTA-002’s clinical and commercial performance?
• What is GTA-002’s clinical trial status in each individual indications such as Acute myeloid leukaemia, Multiple myeloma, Colorectal cancer, Malignant melanoma, and Systemic lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GTA-002 Manufacturers?
• What are the key designations that have been granted to GTA-002 for potential indications? How are they going to impact GTA-002’s penetration in various geographies?
• What is the current and forecasted GTA-002 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of GTA-002 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to GTA-002 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is GTA-002? What is the duration of therapy and what are the geographical variations in cost per patient?